Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 77, Issue 1, 2018, Pages 133-140

  Wang Renault, Shu Fang ^a,b,c   Boudaoud, Saida ^b,c   Nocturne, Gaétane ^b,c   Roche, Elodie ^a   Sigrist, Nelly ^a   Daviaud, Christian ^a   Tinggaard, Andreas Bugge ^a,d   Renault, Victor ^e   Deleuze, Jean François ^a,e   Mariette, Xavier ^b,c   Tost, Jörg ^a  

^a CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d AARHUS UNIVERSITY   (Denmark)

^e FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD19 ANTIGEN; MICRORNA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; EPITHELIUM CELL; ETHNICITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; T LYMPHOCYTE; AGED; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SJOGREN'S SYNDROME;

EID: 85039851612     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211417     Document Type: Article

References (48)

1. Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004;33:39-43.
2. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren's syndrome: A systematic review and meta-Analysis. Ann Rheum Dis 2015;74:1983-9.
3. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013;9:544-56.
4. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013;45:1284-92.
5. Li Y, Zhang K, Chen H, et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet 2013;45:1361-5.
6. Taylor KE, Wong Q, Levine DM, et al. Genome-wide association analysis reveals genetic heterogeneity of Sjögren's syndrome according to ancestry. Arthritis Rheumatol 2017;69:1294-305.
7. Miceli-Richard C, Wang-Renault SF, Boudaoud S, et al. Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome. Ann Rheum Dis 2016;75:933-40.
8. Altorok N, Coit P, Hughes T, et al. Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjögren's syndrome. Arthritis Rheumatol 2014;66:731-9.
9. Imgenberg-Kreuz J, Sandling JK, Almlöf JC, et al. Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes. Ann Rheum Dis 2016;75:2029-36.
10. van Rooij E. The art of microRNA research. Circ Res 2011;108:219-34.
11. Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cell Mol Life Sci 2016;73:2041-51.
12. Chen JQ, Papp G, Szodoray P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev 2016;15:1171-80.
13. Alevizos I, Alexander S, Turner RJ, et al. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. Arthritis Rheum 2011;63:535-44.
14. Peng L, Ma W, Yi F, et al. MicroRNA profiling in Chinese patients with primary Sjögren syndrome reveals elevated miRNA-181a in peripheral blood mononuclear cells. J Rheumatol 2014;41:2208-13.
15. Shi H, Zheng LY, Zhang P, et al. miR-146a and miR-155 expression in PBMCs from patients with Sjögren's syndrome. J Oral Pathol Med 2014;43:792-7.
16. Pauley KM, Stewart CM, Gauna AE, et al. Altered miR-146a expression in Sjögren's syndrome and its functional role in innate immunity. Eur J Immunol 2011;41:2029-39.
17. Williams AE, Choi K, Chan AL, et al. Sjögren's syndrome-Associated microRNAs in CD14(+) monocytes unveils targeted TGF?signaling. Arthritis Res Ther 2016;18:95.
18. Mestdagh P, Hartmann N, Baeriswyl L, et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 2014;11:809-15.
19. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
20. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
21. Pfaffl MW. Quantification strategies in real-Time PCR, In. Bustin SA, ed. A-Z of quantitative PCR La Jolla. CA, USA: International University Line, 2004:87-112.
22. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT -qPCR data normalization. Genome Biol 2009;10:R64.
23. Zilahi E, Tarr T, Papp G, et al. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjögren's syndrome. Immunol Lett 2012;141:165-8.
24. Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007;56:1134-44.
25. Alsaleh G, François A, Philippe L, et al. MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts. PLoS One 2014;9:e111266.
26. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011;208:1189-201.
27. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009;60:1065-75.
28. Li J, Wan Y, Guo Q, et al. Altered microRNA expression profile with miR-146a upregulation in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R81.
29. Murugaiyan G, Beynon V, Mittal A, et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2011;187:2213-21.
30. Kurowska-Stolarska M, Alivernini S, Ballantine LE, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A 2011;108:11193-8.
31. Filková M, Aradi B, Senolt L, et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis 2014;73:1898-904.
32. Long L, Yu P, Liu Y, et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol 2013;2013:1-10.
33. Szabó K, Papp G, Szántó A, et al. A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 2016;183:76-89.
34. Verstappen GM, Meiners PM, Corneth OBJ, et al. Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjogren's syndrome. Arthritis & rheumatology 2017. [Epub ahead of print].
35. Tasaki S, Suzuki K, Nishikawa A, et al. Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome. Ann Rheum Dis 2017;76:1458-66.
36. Chafin CB, Regna NL, Hammond SE, et al. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int Immunopharmacol 2013;17:894-906.
37. García-Rodríguez S, Arias-Santiago S, Blasco-Morente G, et al. Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity. J Eur Acad Dermatol Venereol 2017;31:312-22.
38. Løvendorf MB, Zibert JR, Gyldenløve M, et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014;75:133-9.
39. Simpson LJ, Ansel KM. MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest 2015;125:2242-9.
40. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008;9:405-14.
41. Alevizos I, Illei GG. MicroRNAs in Sjögren's syndrome as a prototypic autoimmune disease. Autoimmun Rev 2010;9:618-21.
42. Zhu G, Chai J, Ma L, et al. Downregulated microRNA-32 expression induced by high glucose inhibits cell cycle progression via PTEN upregulation and Akt inactivation in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun 2013;433:526-31.
43. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol 2004;202:496-502.
44. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol 2008;67:185-92.
45. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71.
46. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
47. Sharma A, Kiripolsky J, Klimatcheva E, et al. Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction. Clin Immunol 2016;164:85-94.
48. Steri M, Orrù V, Idda ML, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med 2017;376:1615-26.